Skip to main content
Clinical Trials/CTRI/2016/01/006486
CTRI/2016/01/006486
Recruiting
Phase 4

Comparative Evaluation of Efficacy and Safety of Metformin Glimepiride combination (s) and Sitagliptin Metformin Combination Treatment in Patients with Type 2 Diabetes: A open label, randomized, multicentre, Investigator Initiated Study in Indian Population

SV Limited0 sites270 target enrollmentTBD

Overview

Phase
Phase 4
Intervention
Not specified
Conditions
Health Condition 1: null- Type 2 Diabetes Mellitus
Sponsor
SV Limited
Enrollment
270
Status
Recruiting
Last Updated
4 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
4 years ago
Study Type
Interventional

Investigators

Sponsor
SV Limited

Eligibility Criteria

Inclusion Criteria

  • 1\.Subjects aged between 18 â?? 65 years of either sex.
  • 2\.Subjects newly diagnosed with Type 2 Diabetes.
  • 3\.Subjects with uncontrolled Type 2 Diabetes currently on metformin monotherapy. Uncontrolled diabetes as:
  • FBS ( \>\= 126mg/dL and \<\= 200 mg/dL) and or 2 h post prandial (\>\= 200 mg/dL)
  • HbA1c levels \>\= 7\.5% and \<\= 10% at screening (Visit 1\).
  • 4\.Women of childbearing potential who agree to not to become pregnant and use an appropriate contraceptive method (hormonal, IUD, or diaphragm).
  • 5\.Subjects willing to sign the Informed Consent Form and comply with the study visit as per protocol and perform 5\-point home blood glucose monitoring as per protocol.
  • 6\.Subjects willing to provide audiovisual recording of the consent process.
  • 7\.Agree to follow recommended diet plan and physical activity instructions throughout the study.

Exclusion Criteria

  • 1\.Subjects with type 1 diabetes or secondary forms of diabetes.
  • 2\.Patients requiring insulin for glycemic control and or History of Insulin usage during 3 months preceding enrollment.
  • 3\.A pregnant or lactating women.
  • 4\.A female subject intends to become pregnant during the expected study duration.
  • 5\.Fasting Blood Sugar ( \< 126mg/dL) and or 2 h post prandial ( \< 200 mg/dL).
  • 6\.HbA1c levels \<\= 7\.5% and \>\= 10% at screening.
  • 7\.Subjects who are currently on a combination therapy with 2 or more oral anti\-diabetic agents.
  • 8\.Subjects with history of diabetic ketoacidosis and vascular complications.
  • 9\.Clinically significant renal disease with serum creatinine \> 1\.5 ULN.
  • 10\.Clinically significant liver disease with ALT and AST values 2\.5 times ULN.

Outcomes

Primary Outcomes

Not specified

Similar Trials